Integra LifeSciences Holdings Corporation completed its acquisition of ACell Inc. on January 20 for an upfront cash payment of $300 million and additional cash payments of up to $100 million upon the achievement of certain revenue growth milestones.
Integra LifeSciences is a global leader in medical technology, offering innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.
ACell is an innovative regenerative medicine company with a product portfolio based on a proprietary porcine urinary bladder matrix platform technology, MatriStem UBMTM. The acquisition of ACell is the next step in the expansion of Integra’s Orthopedics and Tissue Technologies segment.
The S&C team advising on M&A matters was led by Melissa Sawyer and included associates Benjamin Goodchild and Beini Chen. Davis Wang advised on tax matters; Heather Coleman advised on executive compensation; Mehdi Ansari advised on intellectual property matters; Renata Hesse advised on antitrust matters; special counsel Eric Queen advised on HSR matters; and special counsel Matt Brennan advised on representation and warranty insurance matters.